Currently, sacubitril/valsartan, a combined neprilysin inhibitor and angiotensin II (AngII) AT1 receptor antagonist (ARNI), showed beneficial effects in HF, leading to a reduction in hospitalizations and mortality, especially in HF with reduced ejection fraction (HFrEF) [52]. This evidence concerns the gene AGT and hydrops fetalis.